1. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer
- Author
-
Simons, Janine M., van Nijnatten, Thiemo J. A., van der Pol, Carmen C., van Diest, Paul J., Jager, Agnes, van Klaveren, David, Kam, Boen L. R., Lobbes, Marc B., de Boer, Maaike, Verhoef, Cees, Sars, Paul R. A., Heijmans, Harald J., van Haaren, Els R. M., Vles, Wouter J., Contant, Caroline M. E., Menke-Pluijmers, Marian B. E., Smit, Leonie H. M., Kelder, Wendy, Boskamp, Marike, Koppert, Linetta B., Luiten, Ernest J. T., Smidt, Marjolein L., RS: GROW - R2 - Basic and Translational Cancer Biology, Surgery, MUMC+: DA BV AIOS Radiologie (9), Beeldvorming, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), MUMC+: MA Heelkunde (9), Radiotherapy, Medical Oncology, Public Health, and Radiology & Nuclear Medicine
- Subjects
Sentinel Lymph Node Biopsy ,Breast Neoplasms ,Middle Aged ,Neoadjuvant Therapy ,Iodine Radioisotopes ,SDG 3 - Good Health and Well-being ,Lymphatic Metastasis ,Axilla ,Humans ,Lymph Node Excision ,Surgery ,Female ,Prospective Studies ,Thyroid Neoplasms ,Lymph Nodes ,Sentinel Lymph Node ,Iodine - Abstract
ImportanceSeveral less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients with initially clinically node-positive (cN+) breast cancer, but these procedures may fail to detect residual disease. Owing to the lack of high-level evidence, it is not yet clear which procedure is most optimal to replace ALND.ObjectiveTo determine the diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS), a targeted axillary dissection procedure.Design, Setting, and ParticipantsThis was a prospective, multicenter, noninferiority, diagnostic accuracy trial conducted from March 1, 2017, to December 31, 2019. Patients were included within 14 institutions (general, teaching, and academic) throughout the Netherlands. Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter 5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and/or level II axillary nodes; cN3b, metastases to ipsilateral level I and/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion. Data were analyzed from July 2020 to December 2021.InterventionPre-NAC, the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the marked lymph node (ie, RISAS procedure) was performed, followed by ALND.Main Outcomes and MeasuresThe identification rate, false-negative rate (FNR), and negative predictive value (NPV) were calculated for all 3 procedures: RISAS, SLNB, and MARI. The noninferiority margin of the observed FNR was 6.25% for the RISAS procedure.ResultsA total of 212 patients (median [range] age, 52 [22-77] years) who had cN+ breast cancer underwent the RISAS procedure and ALND. The identification rate of the RISAS procedure was 98.2% (223 of 227). The identification rates of SLNB and MARI were 86.4% (197 of 228) and 94.1% (224 of 238), respectively. FNR of the RISAS procedure was 3.5% (5 of 144; 90% CI, 1.38-7.16), and NPV was 92.8% (64 of 69; 90% CI, 85.37-97.10), compared with an FNR of 17.9% (22 of 123; 90% CI, 12.4%-24.5%) and NPV of 72.8% (59 of 81; 90% CI, 63.5%-80.8%) for SLNB and an FNR of 7.0% (10 of 143; 90% CI, 3.8%-11.6%) and NPV of 86.3% (63 of 73; 90% CI, 77.9%-92.4%) for the MARI procedure. In a subgroup of 174 patients in whom SLNB and the MARI procedure were successful and ALND was performed, FNR of the RISAS procedure was 2.5% (3 of 118; 90% CI, 0.7%-6.4%), compared with 18.6% (22 of 118; 90% CI, 13.0%-25.5%) for SLNB (P P = .03).Conclusions and RelevanceResults of this diagnostic study suggest that the RISAS procedure was the most feasible and accurate less-invasive procedure for axillary staging after NAC in patients with cN+ breast cancer.
- Published
- 2023